The role of dopamine in the mechanism of action of antidepressant drugs.
about
Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization propertiesTriple reuptake inhibitors: the next generation of antidepressantsObesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature ReviewMemantine: New prospective in bipolar disorder treatmentThe substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophreniaInvited review: the evolution of antidepressant mechanismsEfficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trialsThe other face of depression, reduced positive affect: the role of catecholamines in causation and cureDOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profileTriple Reuptake Inhibitors: A Premise and PromiseSerotonin, inhibition, and negative mood.Dopamine genetic risk score predicts depressive symptoms in healthy adults and adults with depression.Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.Reconsidering anhedonia in depression: lessons from translational neuroscience.Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test.The 5-HT2C receptor as a target for mood disorders.Meta-analyses of genetic studies on major depressive disorder.Comparison of psychological symptoms and serum levels of neurotransmitters in Shanghai adolescents with and without internet addiction disorder: a case-control studyEffect of the adenosine A2A receptor antagonist MSX-3 on motivational disruptions of maternal behavior induced by dopamine antagonism in the early postpartum ratAntidepressant-like effect of Hoodia gordonii in a forced swimming test in mice: evidence for involvement of the monoaminergic systemThe novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.The pharmacogenomics of selective serotonin reuptake inhibitors.Effects of stimulation and blockade of d(2) receptor on depression-like behavior in ovariectomized female rats.Chronic fluoxetine selectively upregulates dopamine D₁-like receptors in the hippocampusStructural and functional models of depression: from sub-types to substrates.Involvement of adrenoceptors, dopamine receptors and AMPA receptors in antidepressant-like action of 7-O-ethylfangchinoline in mice.A possible role for the endocannabinoid system in the neurobiology of depressionCharacterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse.Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems.Mapping anhedonia onto reinforcement learning: a behavioural meta-analysisFailure of memantine to "reverse" quinpirole-induced hypomotility.Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressantsReduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task.Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?Anxiolytic profile of fluoxetine as monitored following repeated administration in animal rat model of chronic mild stress.Role of Reward Sensitivity and Processing in Major Depressive and Bipolar Spectrum Disorders.Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.Serotonin receptors in depression: from A to B.
P2860
Q24603864-195714C3-1901-4698-A780-D2C8A1848143Q24633511-47CACE82-04EF-483D-8C18-F5693CFA5448Q24658248-87ECBB04-2A1F-4008-BC9E-395DEEF51E96Q26771735-983D1201-1690-4DCC-B212-E499FB047851Q26852133-B51F7A01-CA09-4FDE-977B-92AAE861109CQ28210979-E1876189-9312-43A6-BC32-427E44B5C779Q28241221-444479D4-FA45-4A3D-AB2D-CB705018ACB7Q28252146-F6ACCACF-B60A-42D3-99EF-4FE111A3AD63Q28269179-E9029EFC-8E50-4EC3-8034-3FB5B37CDD91Q28293513-1FF95AEE-92DF-48E3-BAE7-DA61F80B56AFQ28972234-556C1B93-4059-4E94-976B-81E427E7C774Q33318080-3C09C22E-D65D-4F99-A0D0-C15074187A31Q33623531-F4ADF139-3835-4BA6-8C81-DCA36878FA09Q33889048-26EF6F9C-3C20-4292-BCCD-A27878A93F5CQ33999301-D5B64533-4929-495D-A98F-12D1229798DAQ34124371-BC525E3D-3AD3-4776-AB3C-7348294268B3Q34390424-C84134CA-E98D-4824-BDD1-A16B2B05BC36Q34546030-6B1594E6-998B-4022-B30F-59340346D55EQ34701323-06736C5A-852A-4E9C-A339-0E0D7004FB2BQ34712943-C7AF4EA4-15BB-4A33-8864-1A7315BDCC6BQ34802194-DDB2E52C-248E-4210-B455-4C3FD7CCB6D9Q34886531-1B08DC2F-EFA0-4EAB-AA96-A8473D8A6D19Q35532003-FB95807B-41A8-4F01-95C4-5B00D998DBCCQ35757723-760707AC-0CA4-42BA-8D2A-18D4CEA6A16CQ35864182-65233E76-3FC1-49D5-8903-3FF8FD5F3BC8Q35892753-AB188F56-C84F-4A27-B91B-A51FEB25FFB3Q36018497-CEBCD5AA-55B7-479F-B508-518B00CADCEFQ36044838-9D7DC638-290B-4864-96BE-03632AB04031Q36316074-A59A7E0C-5197-48DE-A888-E6E1379D162AQ36369800-DEB50B3A-110A-45CB-BD88-B0ED3F70086BQ36871849-068FE782-A349-4498-A82C-402E4FBDB3EEQ36982911-28D788FF-D3C9-4143-B6CC-AECEEC524946Q37033976-4EDE4135-AC74-49F9-90BB-DBDDA722A964Q37071538-EFDA1B82-FE0F-4B47-8B36-701BD7349FC8Q37088803-4E0E2EDD-BB48-4841-8B4F-6CB046E8A855Q37158450-53C1EC14-EA9F-4B56-BCEC-BDAC2ED93189Q37330734-FCFDA7FC-17CC-4DDD-A820-EB5963C72C7BQ37429197-9A4250F6-7564-4DB0-88A3-9C9FB7D6A32CQ37552410-FC946C61-51DC-4358-A43A-ED7437B0F3E8Q37635780-3B57F530-396E-4AD1-81CB-ED81CF0B73CD
P2860
The role of dopamine in the mechanism of action of antidepressant drugs.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The role of dopamine in the mechanism of action of antidepressant drugs.
@ast
The role of dopamine in the mechanism of action of antidepressant drugs.
@en
The role of dopamine in the mechanism of action of antidepressant drugs.
@nl
type
label
The role of dopamine in the mechanism of action of antidepressant drugs.
@ast
The role of dopamine in the mechanism of action of antidepressant drugs.
@en
The role of dopamine in the mechanism of action of antidepressant drugs.
@nl
prefLabel
The role of dopamine in the mechanism of action of antidepressant drugs.
@ast
The role of dopamine in the mechanism of action of antidepressant drugs.
@en
The role of dopamine in the mechanism of action of antidepressant drugs.
@nl
P2093
P1476
The role of dopamine in the mechanism of action of antidepressant drugs.
@en
P2093
P304
P356
10.1016/S0014-2999(00)00566-5
P407
P577
2000-09-01T00:00:00Z